HC Wainwright Increases Enliven Therapeutics (NASDAQ:ELVN) Price Target to $39.00

Enliven Therapeutics (NASDAQ:ELVN) had its target price increased by HC Wainwright from $37.00 to $39.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, BTIG Research assumed coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $38.75.

Enliven Therapeutics Stock Up 0.8 %

Shares of ELVN stock opened at $21.08 on Friday. The company has a 50 day moving average price of $21.31 and a 200-day moving average price of $23.76. Enliven Therapeutics has a 52 week low of $15.96 and a 52 week high of $30.03. The firm has a market capitalization of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. Analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares in the company, valued at $20,629,865.36. This represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,784 shares of company stock valued at $1,610,375 over the last 90 days. 29.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently modified their holdings of the stock. Barclays PLC lifted its holdings in shares of Enliven Therapeutics by 295.8% in the third quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after buying an additional 42,012 shares in the last quarter. Geode Capital Management LLC raised its stake in Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after purchasing an additional 67,813 shares in the last quarter. Ally Bridge Group NY LLC purchased a new stake in Enliven Therapeutics during the third quarter valued at $5,998,000. Patient Square Capital LP purchased a new stake in Enliven Therapeutics during the third quarter valued at $2,313,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Enliven Therapeutics by 10.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after purchasing an additional 24,043 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.